Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIAN-SHAN8: DZD6008 + Sunvozertinib in Advanced NSCLC With EGFR Mutations
NCT07079475Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of DZD6008, sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jul 2025; status: recruiting.
02
Drugs
DZD6008sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07079475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079475.